CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians

Prostate

Volumn 39, Issue 2, 1999, Pages 130-134

  Giovannucci, Edward ^a,b,d   Stampfer, Meir J ^a,b   Chan, Andrew ^a   Krithivas, Krishna ^a   Gann, Peter H ^c   Hennekens, Charles H ^a,b   Kantoff, Philip W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CHANNING LABORATORY   (United States)

Author keywords

Androgen receptor; Benign prostate hyperplasia; CAG repeats; Prospective studies

Indexed keywords

ANDROGEN RECEPTOR;

ARTICLE; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE REPEAT; PHYSICIAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RECEPTOR GENE; RISK ASSESSMENT; RISK FACTOR; TRANSACTIVATION; TRANSCRIPTION REGULATION;

EID: 0033119562     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0045(19990501)39:2<130::aid-pros8>3.0.co;2-%23     Document Type: Article

References (17)

1. Price H, McNeal JE, Stamey TA. Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum Pathol 1990;21:578-585.
2. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J, Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-1191.
3. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-299.
4. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22:3181-3186.
5. n-expanded neuronopathies. Hum Mol Genet 1995;4:523-527.
6. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997;82:3777-3782.
7. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fishbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77-79.
8. Igarashi S, Tanno Y, Onodera O, Yamazaki M, Sato S, Ishikawa A, Miyatani N, Nagashima M, Ishikawa Y, Sahashi K, Ibi T, Miyatake T, Tsuji S. Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. Neurology 1992;42:2300-2302.
9. Coetzee GA, Ross RK. Re: prostate cancer and the androgen receptor [letter]. J Natl Cancer Inst 1994;86:872-873.
10. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94:3320-3323.
11. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57:1194-1198.
12. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-170.
13. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135.
14. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995;26:40-49.
15. Giovannucci E, Platz EA, Stampfer MJ, Chan A, Krithivas K, Kawachi I, Willett WC, Kantoff PW. The CAG repeat with the androgen receptor gene and benign prostatic hyperplasia. Urology 1999;53:121-125.
16. Walsh PC. Treatment of benign prostatic hyperplasia [editorial]. N Engl J Med 1996;335:586-587.
17. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-539.